Adam C Finnefrock
Overview
Explore the profile of Adam C Finnefrock including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
1015
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wang D, Freed D, He X, Li F, Tang A, Cox K, et al.
Sci Transl Med
. 2016 Nov;
8(362):362ra145.
PMID: 27797961
Congenital human cytomegalovirus (HCMV) infection occurs in ~0.64% of infants born each year in the United States and is the leading nongenetic cause of childhood neurodevelopmental disabilities. No licensed HCMV...
2.
Finnefrock A, Freed D, Tang A, Li F, He X, Wu C, et al.
Hum Vaccin Immunother
. 2016 Mar;
12(8):2106-2112.
PMID: 26986197
The Antigenic Domain 2 (AD-2) is a short region near the N-terminus of glycoprotein B of human cytomegalovirus (HCMV). AD-2 has been shown to contain linear epitopes that are targets...
3.
Scott V, Villarreal D, Hutnick N, Walters J, Ragwan E, Bdeir K, et al.
Hum Vaccin Immunother
. 2015 Jul;
11(8):1961-71.
PMID: 26158319
Botulinum neurotoxins (BoNTs) are deadly, toxic proteins produced by the bacterium Clostridium botulinum that can cause significant diseases in humans. The use of the toxic substances as potential bioweapons has...
4.
Brown M, Seitz H, Towne V, Muller M, Finnefrock A
Clin Vaccine Immunol
. 2014 Feb;
21(4):587-93.
PMID: 24574536
Human papillomavirus (HPV) is the etiological agent for all cervical cancers, a significant number of other anogenital cancers, and a growing number of head and neck cancers. Two licensed vaccines...
5.
Armistead J, Morlais I, Mathias D, Jardim J, Joy J, Fridman A, et al.
Infect Immun
. 2014 Jan;
82(2):818-29.
PMID: 24478095
Malaria transmission-blocking vaccines (TBVs) represent a promising approach for the elimination and eradication of this disease. AnAPN1 is a lead TBV candidate that targets a surface antigen on the midgut...
6.
Freed D, Tang Q, Tang A, Li F, He X, Huang Z, et al.
Proc Natl Acad Sci U S A
. 2013 Dec;
110(51):E4997-5005.
PMID: 24297878
Human cytomegalovirus (HCMV) can cause serious morbidity/mortality in transplant patients, and congenital HCMV infection can lead to birth defects. Developing an effective HCMV vaccine is a high medical priority. One...
7.
Fridman A, Finnefrock A, Peruzzi D, Pak I, La Monica N, Bagchi A, et al.
Oncoimmunology
. 2012 Dec;
1(8):1258-1270.
PMID: 23243589
Functional T-cell epitope discovery is a key process for the development of novel immunotherapies, particularly for cancer immunology. In silico epitope prediction is a common strategy to try to achieve...
8.
Towne V, Zhao Q, Brown M, Finnefrock A
J Immunol Methods
. 2012 Nov;
388(1-2):1-7.
PMID: 23159495
This paper describes an approach to surface plasmon resonance (SPR) based epitope mapping, also referred to as pairwise antibody footprinting, involving the direct immobilization of an antigen-specific primary mAb to...
9.
Fu T, Wang D, Freed D, Tang A, Li F, He X, et al.
Vaccine
. 2012 Oct;
30(52):7469-74.
PMID: 23107592
Maternal immunity to human cytomegalovirus (HCMV) prior to conception is ~70% protective against congenital transmission and in utero infection of HCMV. Both functional antibodies capable of neutralizing virus and effective...
10.
Wang D, Li F, Freed D, Finnefrock A, Tang A, Grimes S, et al.
Vaccine
. 2011 Sep;
29(48):9075-80.
PMID: 21945962
Naturally acquired immunity significantly reduces the risk of congenital cytomegalovirus (CMV) infection in future pregnancies. An immune response comparable to that of natural infection has been used as a benchmark...